Adaptive Biotechnologies Corporation

University of California

Oregon Health & Science University

Francois Pepin

Malek Faham

Mark Klinger

Martin Moorhead

Victoria Carlton

Paul T Spellman

Obi L Griffith

Oana M Enache

The invention is directed to a method of selecting disease-correlated clonotypes that have a reduced likelihood of producing a false positive signal of relapse when, used to monitor minimal residual disease. In accordance with the invention, candidate correlating clonotype are obtained from a patient, the rarity of each is determined either by comparison with a clonotype database or a clonotype model, and one or more of the rarest of such clonotypes are used to monitor the minimal residual disease.

Rare clonotypes and uses thereof

The invention is directed to methods of monitoring B-cell lymphoid proliferative disorders, such as B-cell acute lymphoblastic leukemias, by measuring the presence, absence and/or levels of correlating, or index, clonotypes and related clonotypes that have evolved therefrom, for example, as part of the disease condition. In one aspect, such methods are implemented by generating sequencing-based clonotype profiles and determining frequencies of correlating, or index, clonotypes present, including new clonotypes that have evolved therefrom, particularly, in the case of B-cell ALL, by VH substitution. The invention also includes use of such monitoring information to modify treatment status of a patient.

Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia

Growing community of inventors

San Bruno, CA, United States of America

Francois Pepin